{"filing":{"accession_number":"0001193125-26-285498","cik":"0001604464","ticker":"ATRA","company_name":"Atara Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"atra-20260622.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526285498/atra-20260622.htm"},"events":[{"id":14252,"run_id":12676,"accession_number":"0001193125-26-285498","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses two executive changes: the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO and principal accounting officer (effective June 26, 2026). While both events are disclosed, the principal action centers on the appointment of Sarney to fill the critical CFO and principal accounting officer roles, making exec_appointment the most salient classification. The departure is secondary context to the appointment action.","company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11625,"accession_number":"0001193125-26-285498","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of CertainOfficers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two executive changes: the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO and principal accounting officer (effective June 26, 2026). While both events are disclosed, the principal action centers on the appointment of Sarney to fill the critical CFO and principal accounting officer roles, making exec_appointment the most salient classification. The departure is secondary context to the appointment action.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:17:01.793640+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11625,"accession_number":"0001193125-26-285498","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of CertainOfficers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two executive changes: the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO and principal accounting officer (effective June 26, 2026). While both events are disclosed, the principal action centers on the appointment of Sarney to fill the critical CFO and principal accounting officer roles, making exec_appointment the most salient classification. The departure is secondary context to the appointment action.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:17:01.793640+00:00","company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","filing_date":"2026-06-26"}]}